Last reviewed · How we verify
Iodixanol, Ioversol, Iopromide
These are iodinated contrast media that increase radiodensity to enhance visualization of blood vessels and organs during imaging procedures.
These are iodinated contrast media that increase radiodensity to enhance visualization of blood vessels and organs during imaging procedures. Used for Coronary angiography and percutaneous coronary intervention, Peripheral vascular angiography, Cerebral angiography.
At a glance
| Generic name | Iodixanol, Ioversol, Iopromide |
|---|---|
| Sponsor | GE Healthcare |
| Drug class | Iodinated contrast media |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Iodixanol, ioversol, and iopromide are non-ionic, iodinated radiographic contrast agents used in angiography and other imaging studies. The iodine atoms have high atomic number and attenuate X-rays effectively, creating enhanced contrast between vascular structures and surrounding tissues. They are administered intravenously and distribute throughout the vascular and extracellular compartments to improve diagnostic imaging quality.
Approved indications
- Coronary angiography and percutaneous coronary intervention
- Peripheral vascular angiography
- Cerebral angiography
- Renal angiography
- Computed tomography imaging enhancement
Common side effects
- Contrast-induced nephropathy
- Allergic reaction (mild)
- Anaphylaxis
- Nausea and vomiting
- Flushing and warmth sensation
- Hypotension
Key clinical trials
- Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)
- Comparison of Icg's Route of Administration During Laparoscopic Cholecystectomy (NA)
- Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodixanol, Ioversol, Iopromide CI brief — competitive landscape report
- Iodixanol, Ioversol, Iopromide updates RSS · CI watch RSS
- GE Healthcare portfolio CI